Status:
COMPLETED
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Lead Sponsor:
Bavarian Nordic
Collaborating Sponsors:
Therion Biologics Corporation
National Cancer Institute (NCI)
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
PROSTVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the immune system can be taught to fight cancer by directing the immune system to attack specific targets foun...
Eligibility Criteria
Inclusion
- Male patients \> 18 years of age who have been vaccinated against smallpox;
- Histological confirmation of adenocarcinoma of the prostate with evidence of metastatic disease including either of the following: Lymph node metastasis measurable by CT and/or Bone metastasis evaluable by bone scan;
- Despite hormone therapy, there is evidence of two consecutive increases in PSA (Prostate Specific Antigen);
- Gleason Score of 7 or lower at initial diagnosis.
- Please note that there are additional eligibility criteria that you must meet to qualify.
- If you do qualify to participate, study personnel will explain the trial in detail and answer any questions you may have. You can then decide whether or not you wish to participate. If you do not qualify for the trial, study personnel will explain the reasons.
Exclusion
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2009
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00078585
Start Date
November 1 2003
End Date
January 1 2009
Last Update
September 11 2017
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology Centers of Alabama
Homewood, Alabama, United States, 35209
2
Alaska Clinical Research Center
Anchorage, Alaska, United States, 99508
3
Urology Associates of Central California
Fresno, California, United States, 93720
4
San Diego Urology Center
La Mesa, California, United States, 91942